Celmatix
New York, US · Founded 2010 · Delaware corporation · 1 known investors
Celmatix Therapeutics developed a discovery portfolio focused on women's health, including therapeutic programs for infertility, endometriosis, and ovarian aging. The company's pipeline included an oral FSH receptor agonist, a JNK inhibitor, and AMH-targeting antibodies.
Founders & leadership
Celmatix was founded in 2010 by Piraye Yurttas Beim.
PY
Piraye Yurttas BeimFounder
Board
SW
Steven WinickBoard director
LT
Laura Towart BandakBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$15.6M disclosed across 4 rounds · 2012–2016
▶$4.8MraisedApr 2016 · 1 investors · BiotechnologyRule 506(b)
▶$4.8MraisedApr 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Piraye Yurttas BeimExecutive Officer, Director
- Laura BandakDirector
- Steven J. WinickDirector
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Mar 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.8MraisedSep 2015 · 5 investors · BiotechnologyRule 506(b)
▶$3.8MraisedSep 2015 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Piraye Yurttas BeimExecutive Officer, Director
- Steven J. WinickDirector
- Laura BandakDirector
- Offering amount
- $5.2M
- Amount sold
- $3.8M
- First sale
- Aug 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedJul 2015 · 6 investors · BiotechnologyRule 506(b)
▶$5.5MraisedJul 2015 · 6 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Piraye Yurttas BeimExecutive Officer, Director
- Steven WinickDirector
- Laura Towart BandakDirector
- Offering amount
- $5.5M
- Amount sold
- $5.5M
- First sale
- Dec 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$1.5MraisedMar 2012 · 10 investors · BiotechnologyRule 506(b)
▶$1.5MraisedMar 2012 · 10 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Piraye Yurttas BeimExecutive Officer, Director
- Laura Towart BandakExecutive Officer, Director
- Steven WinickDirector
- Offering amount
- $1.5M
- Amount sold
- $1.5M
- First sale
- Feb 2012
- Incorporated
- Corporation, Delaware, 2010
- Federal exemptions
- 06
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlap
Exelixis31 shared keywordsExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.
IQVIA27 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Companies competing with Celmatix for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Celmatix do?
- Celmatix Therapeutics developed a discovery portfolio focused on women's health, including therapeutic programs for infertility, endometriosis, and ovarian aging. The company's pipeline included an oral FSH receptor agonist, a JNK inhibitor, and AMH-targeting antibodies.
- Who founded Celmatix?
- Celmatix was founded by Piraye Yurttas Beim in 2010.
- Who are Celmatix's investors?
- Celmatix's investors include Lauder Partners.
- How much funding has Celmatix raised?
- Celmatix has disclosed $15.6M raised across 4 rounds.
- Where is Celmatix headquartered?
- Celmatix is headquartered in New York, US.